Company Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease.
In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Country | Netherlands |
| Founded | 1998 |
| IPO Date | Jun 20, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 480 |
| CEO | Matthew Kapusta |
Contact Details
Address: Paasheuvelweg 25 Amsterdam, 1105 BP Netherlands | |
| Phone | 31 20 240 6000 |
| Website | uniqure.com |
Stock Details
| Ticker Symbol | QURE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590560 |
| CUSIP Number | N90064101 |
| ISIN Number | NL0010696654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christian Klemt | Chief Financial Officer, Principal Financial Officer and GM of Amsterdam Site |
| Richard Porter Ph.D. | Chief Business and Scientific Officer |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Erin Boyer | Chief People and Culture Officer |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Eileen Sawyer | Vice President of Global Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 8-K | Current Report |